Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Relative Vaccine Effectiveness of Adjuvanted Inactivated Influenza Vaccine (aIIV) vs High-Dose Inactivated Influenza Vaccine (HD-IIV) for Prevention of Lab-Confirmed Influenza Among Adults ≥65 Years of Age in the United States

NCT06029933 is registered in ClinicalTrials.gov with Kaiser Permanente as lead sponsor.

NCT NCT06029933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06029933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Relative Vaccine Effectiveness of Adjuvanted Inactivated Influenza Vaccine (aIIV) vs High-Dose Inactivated Influenza Vaccine (HD-IIV) for Prevention of Lab-Confirmed Influenza Among Adults ≥65 Years of Age in the United States
Lead sponsor
Kaiser Permanente
Phase
Observational
Overall status
Recruiting
Start date
August 17, 2023
Completion date
May 31, 2028
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular events, community-acquired pneumonia, influenza